Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nitric oxide synthase 2, inducible | Starlite/ChEMBL | References |
Homo sapiens | nitric oxide synthase 1 (neuronal) | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0059 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0059 | 1 | 0.5 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0059 | 1 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0059 | 1 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0059 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0059 | 1 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0059 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0059 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0059 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.0059 | 1 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0059 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0059 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0052 | 0.7743 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0059 | 1 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.0037 | 0.2407 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0029 | 0 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0059 | 1 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0059 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0059 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0059 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0037 | 0.2407 | 0.2407 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0059 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.003 | 0.0151 | 0.0151 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0059 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0059 | 1 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0029 | 0 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0059 | 1 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0052 | 0.7743 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0059 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.05 uM | Inhibitory activity of compound against human inducible nitiric oxide synthase | ChEMBL. | 12620067 |
IC50 (binding) | = 0.05 uM | Inhibitory activity of compound against human inducible nitiric oxide synthase | ChEMBL. | 12620067 |
IC50 (binding) | = 3.5 uM | Inhibitory activity against human neuronal nitiric oxide synthase | ChEMBL. | 12620067 |
IC50 (binding) | = 3.5 uM | Inhibitory activity against human neuronal nitiric oxide synthase | ChEMBL. | 12620067 |
IC50 (functional) | = 4 uM | Inhibitory activity against synthesis of inducible nitiric oxide synthase by DLD-1 cells | ChEMBL. | 12620067 |
IC50 (functional) | = 4 uM | Inhibitory activity against synthesis of inducible nitiric oxide synthase by DLD-1 cells | ChEMBL. | 12620067 |
ID50 (functional) | > 30 uM kg-1 | Inhibition of LPS induced nitrite production in rat following 4 hr of oral administration | ChEMBL. | 12620067 |
Inhibition (binding) | < 25 % | Inhibitory activity of 100 uM compound against human endothelial nitiric oxide synthase | ChEMBL. | 12620067 |
Inhibition (binding) | < 25 % | Inhibitory activity of 100 uM compound against human endothelial nitiric oxide synthase | ChEMBL. | 12620067 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 12620067 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.